Early Studies Presented for Conformal Medical CLAAS Left Atrial Appendage Closure Technology
October 15, 2020—Conformal Medical, Inc. announced that clinical data from two first-in-human studies of the company's next-generation CLAAS left atrial appendage closure (LAAC) technology were presented in two abstracts by Vivek Reddy, MD, and William Gray, MD, at TCT Connect, the 32nd annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation held online October 14-18, 2020.
MITHRAS Evaluates Interventional Closure of Residual Atrial Septal Defect After TMVR
October 15, 2020—The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in 6-minute walking distance.
NuVera Medical Presents Data From FIH Feasibility Study of NuVision 4D ICE Catheter
October 14, 2020—NuVera Medical, Inc., a portfolio company of Shifamed LLC focused on developing four-dimensional (4D) intracardiac echocardiography (ICE) imaging for transcatheter cardiac interventions, announced the presentation of results from the company’s first-in-human (FIH) feasibility study.
Medtronic Partners With The Foundry to Develop Mitral Valve Repair Technology
October 14, 2020—Medtronic announced a partnership with The Foundry, a medical device company incubator based in Menlo Park, California, to invest in and create a company with the goal of developing a transcatheter mitral repair (TMVR) technology.
Cardiac Dimensions Receives Financing to Accelerate Commercialization of Carillon System in Europe and Australia
September 29, 2020—Cardiac Dimensions announced the company has closed a $17.5 million Series C financing to support the commercialization of the company’s Carillon mitral contour system to treat functional mitral regurgitation (FMR) in patients with heart failure.
SCAI Bifurcation Club Formed to Promote Worldwide Excellence in Coronary Artery Bifurcation Interventions
September 28, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the formation of the SCAI Bifurcation Club, an initiative dedicated to promoting excellence in coronary artery bifurcation interventions worldwide through innovation, research, technologic advances, education, point-of-care tools, and production of consensus documents and guidelines.
BioVentrix Resumes Pivotal ALIVE Trial Following COVID-19 Pause
September 2, 2020—BioVentrix, Inc. announced that the company has resumed the pivotal ALIVE trial studying the company’s LIVE (less-invasive ventricular enhancement) therapy using the Revivent TC transcatheter ventricular enhancement system.
Conformal Medical Secures Financing to Support Pivotal Trial of CLAAS Technology
August 6, 2020—Conformal Medical, Inc. announced it has secured $85 million in Series C financing, which will be used to support the company’s United States pivotal trial of its next-generation Conformal left atrial appendage seal (CLAAS) technology in patients with atrial fibrillation (AFib).
Keystone Heart Launches TriGuard 3 Cerebral Embolic Protection Device in Europe
July 29, 2020—Keystone Heart, Ltd., a Venus Medtech company, announced the completion of the first commercial case using the TriGuard 3 cerebral embolic protection (CEP) device, which is designed to minimize the risk of cerebral damage during transcatheter heart procedures.
Canon Medical Introduces New Configuration of Aquilion One/Genesis Edition Cardiac CT Solution
July 17, 2020—Canon Medical Systems USA, Inc. announced the introduction of a new configuration of the Aquilion One/Genesis Edition, an artificial intelligence–powered wide-area CT system for structural and coronary imaging.
IDE Approved for Trial of Carag’s Transcatheter Bioresorbable Septal Occluder
July 1, 2020—Carag AG, a Switzerland-based medical device company, announced it has received FDA investigational device exemption approval for the Carag bioresorbable septal occluder (CBSO), the company’s transcatheter septal occluder with a bioresorbable, metal-free framework.
Protaryx Receives Funding to Develop Technology for Left Atrial Access in Transcatheter Cardiac Procedures
June 30, 2020—Protaryx Medical announced that it has raised $8.3 million in funding to develop the company’s first-in-class device for precision transseptal access to the left atrium during structural heart and catheter ablation procedures.
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in Europe.